Brock Jane E, Hornick Jason L, Richardson Andrea L, Dillon Deborah A, Lester Susan C
Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Am J Clin Pathol. 2009 Sep;132(3):396-401. doi: 10.1309/AJCPSKFWOLPPMEU9.
Clinical therapies for breast cancer are guided by estrogen receptor (ER) status determined by immunohistochemical analysis. A previous retrospective study comparing the recently generated rabbit SP1 monoclonal antibody (MAb) with the conventionally used mouse 1D5 MAb reported that 8% of breast carcinomas were SP1+/1D5- (correlating with good outcomes), and 2% were SP1-/1D5+ (correlating with poorer outcomes). This study on mostly previously frozen tissue implied that 1D5 fails to identify some women who may benefit from endocrine therapy. The current prospective study compared SP1 and 1D5 immunostaining on routinely processed consecutive cases of breast carcinoma. ER was classified using the same positive threshold used in the prior study (<1% negative; > or = 1% positive). Of 508 carcinomas, 2 were SP1+/1D5-, and none were SP1-/1D5+. Although SP1 is our preferred antibody, with more intense nuclear staining, both MAbs give similar results in tissue from routine clinical samples with discrepant results in fewer than 0.5% of cases.
乳腺癌的临床治疗是根据免疫组织化学分析所确定的雌激素受体（ER）状态来指导的。一项先前的回顾性研究比较了最近产生的兔SP1单克隆抗体（MAb）与常规使用的小鼠1D5 MAb，该研究报告称，8%的乳腺癌为SP1+/1D5-（与良好预后相关），2%为SP1-/1D5+（与较差预后相关）。这项主要针对先前冷冻组织的研究表明，1D5无法识别出一些可能从内分泌治疗中获益的女性。当前的前瞻性研究比较了SP1和1D5在常规处理的连续乳腺癌病例上的免疫染色情况。ER的分类采用了先前研究中相同的阳性阈值（阴性<1%；阳性≥1%）。在508例癌组织中，有2例为SP1+/1D5-，无SP1-/1D5+的病例。尽管SP1是我们首选的抗体，其核染色更强，但在常规临床样本组织中，两种单克隆抗体给出的结果相似，结果不一致的病例不到0.5%。
